pharma · Carcinoma, Non-Small-Cell Lung
Barinthus Biotherapeutics
Centus Biotherapeutics Europe Limited
Centus Biotherapeutics Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Carcinoma, Non-Small-Cell Lung. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 pat
Harwell, GB HQ
2016 Founded
36 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Harwell, GB
- Founded
- 2016
- Employees
- 36
- Programs
- 1
- Drugs
- 1
- Patents
- 0
FKB238 (bevacizumab)
Phase 3 · small molecule · Carcinoma, Non-Small-Cell Lung
FKB238 (bevacizumab) for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at Centus Biotherapeutics Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code FKB238-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Centus Biotherapeutics Europe Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Carcinoma, Non-Small-Cell Lung
- Status
- completed
- Trials
- 1